Package Leaflet: Information for the User
Peroxiben 25 mg/g gel
Benzoic peroxide
Read all of this leaflet carefully because it contains important information for you.
This medicine can be obtained without a prescription. However, to get the best results, it should be used properly.
Contents of the package leaflet:
Benzoic peroxide, the active ingredient of this medicine, has antimicrobial and sebostatic activity (regulates fat), and is able to stop the growth of Propionibacterium acne,the microorganism that causes acne.
Peroxiben is indicated for the local symptomatic treatment of moderate vulgar acne in adults and adolescents from 12 years of age.
Do not use Peroxiben
Be careful with Peroxiben
During the first application, you will probably notice mild burning, and some redness and skin peeling.
During the first weeks of treatment, skin peeling suddenly increases in most patients. Normally, it will decrease in one or two days if the treatment is temporarily interrupted. To prevent this effect, it is recommended to start the treatment in a small area, extending it to the affected area after a few days.
In case of mild irritation, applications should be spaced out.
If irritation persists or is intense, stop using Peroxiben and carefully clean the skin with water and soap. If irritation continues after stopping treatment, consult your doctor.
Use of other medicines
Tell your doctor or pharmacist if you are using, or have recently used, other medicines, including those purchased without a prescription.
Do not use Peroxiben with other medicines or cosmetics that have peeling, irritating, and drying effects.
Peroxiben can be combined under medical control with other substances indicated for the treatment of seborrhea and acne.
Pregnancy and breastfeeding
Consult your doctor or pharmacist before using any medicine.
Peroxiben should only be administered to pregnant women when a medical evaluation determines that the benefit outweighs the potential risk, as the safety of benzoic peroxide has not been established.
It is unknown whether Peroxiben is excreted in breast milk, so it should be administered with caution to breastfeeding women and should not be applied to the breast to avoid transfer to the infant.
Driving and using machines
There is no indication that Peroxiben can affect the ability to drive or use machinery.
Adults and adolescents from 12 years of age
After washing the affected area with water and soap, apply a small amount of Peroxiben to the same area with the fingertips, one or two times a day, depending on the intensity of the process and skin tolerance.
It is advisable to start treatment with Peroxiben 25 mg/g gel, switching to Peroxiben 50 mg/g gel or 100 mg/g gel after 3 or 4 weeks, or earlier in case of good tolerance to Peroxiben 25 mg/g gel.
Improvement can usually be observed after 4-6 weeks of treatment. However, longer use may be required.
Children under 12 years of age
Do not use Peroxiben in children under 12 years of age without medical supervision.
Consult your doctor or pharmacist if you have doubts.
If you use more PEROXIBEN than you should
If you have used more Peroxiben than you should, consult your doctor or pharmacist immediately. If you have used more Peroxiben than you should, your skin may become excessively red and painful. In this case, it should be applied more spaced out until this phase has passed. If irritation persists, consult your doctor.
In case of accidental ingestion, do not induce vomiting, rinse your mouth, and seek immediate medical attention.
In case of overdose or accidental ingestion, consult the Toxicology Information Service: Telephone: 91.562.04.20.
If you forget to use PEROXIBEN
If you forget to administer a dose, apply the next one as soon as possible and continue administration as before. Do not administer a double dose to make up for forgotten doses.
Like all medicines, Peroxiben can cause side effects, although not everyone will experience them.
It is very common (in more than 1 in 10 patients) for the patient to feel a mild burning sensation with the first application, and for moderate redness, dryness, and skin peeling to appear after a few days. During the first weeks of treatment, a sudden increase in peeling, redness, itching, and pruritus (itching) may occur in most patients; this is not harmful and usually disappears in one or two days if treatment is temporarily interrupted.
In rare cases (affecting 1 to 10 in 10,000 patients), allergic dermatitis may be observed.
During the authorization period of this medicine, the following side effects have been observed, whose frequency cannot be established with precision. The patient may experience temporary facial inflammation, dermatitis, or rash. In these cases, treatment should be interrupted immediately and the doctor consulted. These reactions are of unknown frequency and are usually reversible.
If you consider that any of the side effects you are suffering from is serious or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Keep out of the reach and sight of children.
Store below 30 ºC.
Do not use Peroxiben after the expiration date shown on the packaging after the abbreviation "CAD". The expiration date is the last day of the month indicated.
Medicines should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Peroxiben
The active ingredient is benzoic peroxide. Each gram of gel contains 25mg of benzoic peroxide.
The other components are glycerol (E-422), aloe vera gel, carbomer, acrylic copolymer, simethicone, sodium hydroxide (E-524), disodium edetate, dioctyl sodium sulfosuccinate, and purified water.
Appearance of the product and packaging content
Peroxiben is presented in the form of a white gel, in a polyethylene tube with a polypropylene cap. Each tube contains 30 grams of gel.
Other presentations
Peroxiben 50 mg/g gel: tubes with 30 or 60 g of gel.
Peroxiben 100 mg/g gel: tubes with 30 or 60 g of gel.
Marketing authorization holder and manufacturer
Holder:
Isdin S.A.
Provençals 33
08019 Barcelona
Spain
Manufacturer:
Antonio Puig S.A.
C/ Berlín 12
Can Torella Industrial Estate
08233 Vacarisses (Barcelona)
Spain
This leaflet was approved in June 2010